The VISION trial showed that Lu-177-PSMA-617 improved survival when added to standard treatment of men with PSMA-positive metastatic castrate-resistant prostate…
Radiopharmaceuticals are en vogue, leaving many radiation oncologists wondering if they should take up the mantle. Unfortunately many currently don’t…
